P2Y12 inhibitor monotherapy in patients undergoing PCI.

26 August 2022 (09:00 - 09:15)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Dominick Joseph Angiolillo

University of Florida College of Medicine – Jacksonville, Jacksonville (United States of America)

5 More presentations in this session

Presentation thumbnail

Reversal agents to improve safety in patients treated with antiplatelet P2Y12 inhibitors.

Professor D. Bhatt (New York City, US)

Presentation thumbnail

Reversal agents to improve safety in patients treated with direct oral anticoagulants (DOACs).

Professor A. Niessner (Vienna, AT)

Presentation thumbnail

Injectable and intravenous P2Y12 inhibitors in patients with acute myocardial infarction.

Professor G. Montalescot (Paris, FR)

Presentation thumbnail

Factor XIa inhibitors: a new approach to anticoagulation in patients with cardiovascular disease.

Doctor J. Weitz (Hamilton, CA)

Presentation thumbnail

Problem-solving in antiplatelet therapy and anticoagulation – discussion.

Access the full session

Session thumbnail

Problem-solving in antiplatelet therapy and anticoagulation

The Event

Event poster

ESC Congress 2022

26 August 2022 09:00 CET

You may be interested in

Congress Session

Dual antiplatelet therapy titration after percutaneous coronary intervention: when to escalate, de-escalate, withdraw, and more

Congress Presentation

A meta-analysis on the efficacy of ticagrelor monotherapy after 3 months of dual antiplatelet therapy vs ticagrelor plus aspirin dual therapy on patients with ACS who underwent PCI

Congress Presentation

DAPT, monotherapy, or more? Rethinking antithrombotic strategies after percutaneous coronary intervention

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources